A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

Sponsor
Genentech, Inc.
Study ID
NCT00109265
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a Phase II, multicenter trial of single-agent treatment with OSI 774 in patients with histologically confirmed, incurable, locally advanced or metastatic breast cancer. Patients must have measurable disease.

Key Dates

First listed
Apr 26, 2005
Start date
May 31, 2001
Status verified
Jun 2013
Completion
Oct 31, 2002

Study Design

Primary purpose
TREATMENT

Related Studies